ARTICLE | Clinical News
Xatral OD once-daily alfuzosin formulation regulatory update
January 29, 2001 8:00 AM UTC
The partners submitted an NDA for SKP’s Xatral OD. The product is approved in Denmark, France, the Netherlands and Switzerland to treat benign prostatic hyperplasia.. The product is formulated with SK...